Hosted on MSN
Pfizer Stock Slips Premarket Despite Completing Metsera Deal; Investors React To BioNTech Stake Cut
・The Metsera buyout brings multiple obesity and cardiometabolic drug candidates into Pfizer’s pipeline, including a GLP-1 nearing Phase 3. ・Pfizer’s BioNTech position was reduced by 54.7%, leaving ...
FRANKFURT (Reuters) -BioNTech said on Thursday that its collaboration with Pfizer has not changed, when asked to comment on a report that Pfizer is looking to sell its stake in the German biotech firm ...
BioNTech SE BNTX has filed a patent infringement lawsuit against Moderna Inc. MRNA, alleging that Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, relies on proprietary technology developed and ...
Pfizer PFE is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $16.93 ...
Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results